Merck's Tulisokibart Met Primary and Key Secondary Endpoints in Phase 2b Study in Patients With Moderate to Severe Hidradenitis Suppurativa
Results mark the first positive Phase 2 data for an anti-TL1A monoclonal antibody in dermatology Tulisokibart was designed to help address immuno-fibrosis, a key...